Phaseline

Companies › Youssef Yammine

Youssef Yammine: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Respiratory; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tranexamic acid
Plasminogen inhibitor
PLGPhase 3Hemorrhage LungMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06266546Tranexamic acidPhase 3Hemorrhage LungRespiratoryMar 2028

Targets

PLG (1)

Companies with the same targets

Ascension Health Jiangsu Jingze Biopharmaceutical Supergene

Companies built like this

Biotest Areteia Therapeutics PureTech Renovion Kringle Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.